Filtered By:
Condition: Heart Failure
Nutrition: Vitamins

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 268 results found since Jan 2013.

The Status and Research Progress on Vitamin D Deficiency and Atrial Fibrillation
Abstract Atrial fibrillation is a common type of arrhythmia and is an important cause of stroke and heart failure. vitamin D is an emerging risk factor of AF, and is implicated in the pathophysiology of atrial fibrillation. It has been established that this vitamin is extensively involved in the regulation of both the renin angiotensin aldosterone system and the immune system. Epidemiological studies have not yet reached a consensus on the possible association between vitamin D deficiency and atrial fibrillation. Better research designs and methods can further clarify the relationship between the two.
Source: Revista Brasileira de Cirurgia Cardiovascular - November 12, 2019 Category: Cardiovascular & Thoracic Surgery Source Type: research

Atrial Fibrillation in Heart Failure
This article explores the relationship between AF and HF and the thromboembolic effect of these diseases. Morbidity and mortality are increased when the 2 conditions are seen together. Stroke risks are significant with AF and all subtypes of HF. This article suggests that all patients with AF and HF should be considered for anticoagulation. Current evidence suggests that non –vitamin K antagonist oral anticoagulants are effective and safe in AF and HF in comparison with warfarin.
Source: Heart Failure Clinics - November 15, 2019 Category: Cardiology Authors: Mohammed Obeidat, Malcolm Burgess, Gregory Y.H. Lip Source Type: research

Preoperative Vitamin D Concentration and Cardiac, Renal, and Infectious Morbidity after Noncardiac Surgery
Conclusions Preoperative vitamin D was not associated with a composite of postoperative 30-day cardiac outcomes. However, there was a significant association between vitamin D deficiency and a composite of infectious complications and decreased kidney function. While renal effects were not clinically meaningful, the effect of vitamin D supplementation on infectious complications requires further study.
Source: Anesthesiology - December 13, 2019 Category: Anesthesiology Source Type: research

Dietary total antioxidant capacity and severity of stenosis in patients with coronary artery disease.
Conclusions: There was a significant association between dietary TAC and severity of stenosis in patients with coronary artery disease. PMID: 31984875 [PubMed - as supplied by publisher]
Source: International Journal for Vitamin and Nutrition Research - January 29, 2020 Category: Nutrition Tags: Int J Vitam Nutr Res Source Type: research

Vitamin D and vascular disease.
Abstract Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide. Vitamin D deficiency has been identified as a potential risk factor for a number of diseases unrelated to the classical skeletal pathophysiology, such as cancer and CVD, but the effects of vitamin D supplementation are less clear. Purpose of this narrative review is to discuss the evidence suggesting an association between vitamin D status and CVD as well as the results of supplementation studies. Vitamin D deficiency has been associated with CVD risk factors such as hypertension, dyslipidemia and diabetes mellitus as well...
Source: Current Vascular Pharmacology - March 16, 2020 Category: Drugs & Pharmacology Authors: Gouni-Berthold I, Berthold HK Tags: Curr Vasc Pharmacol Source Type: research

Risk of left atrial appendage thrombus in patients with atrial fibrillation and chronic kidney disease.
CONCLUSIONS: Despite OAC, patients with concomitant AF and CKD remain at high risk for LAA thrombus formation. PMID: 32207840 [PubMed - as supplied by publisher]
Source: Cardiology Journal - March 23, 2020 Category: Cardiology Authors: Budnik M, Gawałko M, Gorczyca I, Uziębło-Życzkowska B, Krzesińki P, Kochanowski J, Scisło P, Michalska A, Jelonek O, Starzyk K, Jurek A, Kiliszek M, Wożakowska-Kapłon B, Gielerak G, Filipiak KJ, Opolski G, Kapłon-Cieślicka A Tags: Cardiol J Source Type: research

Efficacy and safety of non-vitamin K anticoagulants and warfarin in patients with atrial fibrillation and heart failure: A network meta-analysis
To recommend the proper anticoagulant drug and its dose for patients with atrial fibrillation (AF) and heart failure (HF), we conducted a network meta-analysis (NMA) to make the comparisons among non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin with regard to efficacy (stroke or systemic embolism) and safety (major bleeding).
Source: Thrombosis Research - August 12, 2020 Category: Hematology Authors: Hao Jin, Kongbo Zhu, Lina Wang, Wangjuan Zhou, Hong Zhi Tags: Review Article Source Type: research

Vitamin C: historical perspectives and heart failure
AbstractVitamin C (Vit C) is an ideal antioxidant as it is easily available, water soluble, very potent, least toxic, regenerates other antioxidants particularly Vit E, and acts as a cofactor for different enzymes. It has received much attention due to its ability in limiting reactive oxygen species, oxidative stress, and nitrosative stress, as well as it helps to maintain some of the normal metabolic functions of the cell. However, over 140 clinical trials using Vit C in different pathological conditions such as myocardial infarction, gastritis, diabetes, hypertension, stroke, and cancer have yielded inconsistent results....
Source: Heart Failure Reviews - October 8, 2020 Category: Cardiology Source Type: research

Guideline Adherence and Associated Outcomes in the Treatment of Type 2 Diabetes Mellitus Patients With an Incident Cardiovascular Comorbidity: An Analysis Based on a Large German Claims Dataset
ConclusionOnly a minority of patients with T2DM and an incident CV comorbidity receive a treatment fully adherent with guideline recommendations. This may contribute to high mortality rates in this population in clinical practice.
Source: Diabetes Therapy - March 12, 2021 Category: Endocrinology Source Type: research

Cardiovascular injuries during COVID-19 infection: A PROCESS-compliant case series from the Eastern Morocco
CONCLUSION: Cardiovascular involvement during COVID-19 should not be neglected and are associated with severe outcomes.PMID:33898022 | PMC:PMC8053362 | DOI:10.1016/j.amsu.2021.102309
Source: Annals of Medicine - April 26, 2021 Category: Internal Medicine Authors: Abdelilah El Rhalete Inas Rhazi Amine Bensaid Ikram Zaid Houssam Bkiyer Nabila Ismaili Nouha Elouafi Brahim Housni Source Type: research

Parathormone levels add prognostic ability to N ‐terminal pro‐brain natriuretic peptide in stable coronary patients
ConclusionsParathormone is an independent predictor of cardiovascular events in coronary patients, adding complimentary prognostic information to NT ‐proBNP plasma levels. This predictive value is restricted to patients with high FGF23 plasma levels. This should be considered in the design of future studies in this field.
Source: ESC Heart Failure - May 1, 2021 Category: Cardiology Authors: Carlos Guti érrez‐Landaluce, Álvaro Aceña, Ana Pello, Juan Martínez‐Milla, Óscar González‐Lorenzo, Nieves Tarín, Carmen Cristóbal, Luis M. Blanco‐Colio, José Luis Martín‐Ventura, Ana Huelmos, Marta López‐Castillo, Joaquí Tags: Original Research Article Source Type: research

Atrial thrombus detection on transoesophageal echocardiography in patients with atrial fibrillation undergoing cardioversion or catheter ablation: A pooled analysis of rates and predictors
ConclusionThe prevalence of LAT/LAAT in AF patients undergoing ECV or CA varies widely, mainly due to differences in patient risk profiles and OAC types. Further research should determine whether the predictors of LAT/LAAT detection identified by this study could be used to select patients who require preprocedural TEE.This article is protected by copyright. All rights reserved.
Source: Journal of Cardiovascular Electrophysiology - May 10, 2021 Category: Cardiology Authors: Jean Jacques Noubiap, Thomas A. Agbaedeng, Aude Laetitia Ndoadoumgue, Ulrich Flore Nyaga, Andre Pascal Kengne Tags: ORIGINAL ARTICLES Source Type: research

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news